7 completed, 1 active not recruiting. 5 Phase 2, 3 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Meningococcal group B vaccine: new trials by email Literature Review of Meningococcal group B vaccine trials Research Report on Meningococcal group B vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 1 / Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 750 | 2024-11-05 | 2026-01-20 |
| Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunisation, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1215 | 2023-10-31 | 2026-01-13 |
| Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae Cefixime, Ceftriaxone, Ciprofloxacin - Gonorrhea Male | Phase 2 | Completed | University of North Carolina, Chapel Hill | 65 | 2022-04-18 | 2026-03-02 |
| Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination Meningococcal Group B Vaccine, Placebo - Gonorrhoea | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 52 | 2021-11-01 | 2026-10-21 |
| Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection Meningococcal Group B Vaccine, Placebo - Gonococcal Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2606 | 2020-12-29 | 2026-07-24 |
| Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine Meningococcal Group B Vaccine - Neisseria Gonorrhoeae Infection | Phase 4 | Completed | University of North Carolina, Chapel Hill | 11 | 2019-10-09 | 2021-07-15 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, Meningococcal group B vaccine, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 788 | 2018-10-10 | 2023-11-07 |
| A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults GSK3389245A_LD GROUP, GSK3389245A_HD GROUP, Bexsero - Respiratory Synctial Virus Infections | Phase 1 | Completed | GlaxoSmithKline | 73 | 2015-07-23 | 2018-08-20 |
Gonorrhea (3) · Meningococcal Infections (1)
Sanofi Pasteur, a Sanofi Company (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of North Carolina, Chapel Hill (2) · GlaxoSmithKline (1)
United States (5) · United Kingdom (3) · Brazil (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Honduras (1) · Malawi (1) · Poland (1) · Puerto Rico (1) · Spain (1) · Thailand (1)
PMID 31340042, PMID 40086037, PMID 42049314
2023 (2), 2017 (1), 5UM1AI148576-05 (1), U01AI162457 (1)